UB Paderborn / Katalog / Suche / in CDI

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

Journal of clinical oncology, 2012-03, Vol.30 (9), p.980-988

2012

Link zum Volltext

Verfügbarkeit prüfen

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Journal of clinical oncology, 2011-09, Vol.29 (26), p.3559-3566

2011

Link zum Volltext

Verfügbarkeit prüfen

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Blood, 2014-07, Vol.124 (1), p.49-62

2014

Link zum Volltext

Verfügbarkeit prüfen

Health-Related Quality of Life in Younger Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study Group

Journal of clinical oncology, 2007-05, Vol.25 (13), p.1722-1731

2007

Link zum Volltext

Verfügbarkeit prüfen

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

Blood, 2006-02, Vol.107 (3), p.885-891

2006

Link zum Volltext

Verfügbarkeit prüfen

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

Leukemia, 2019-05, Vol.33 (5), p.1161-1172

2019

Link zum Volltext

Verfügbarkeit prüfen

ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Future oncology (London, England), 2020-04, Vol.16 (10), p.517-523

2020

Link zum Volltext

Verfügbarkeit prüfen

Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

British journal of haematology, 2009-01, Vol.144 (1), p.95-98

2009

Link zum Volltext

Verfügbarkeit prüfen

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Blood, 2011-02, Vol.117 (6), p.1817-1821

2011

Link zum Volltext

Verfügbarkeit prüfen

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial

European journal of haematology, 2017-03, Vol.98 (3), p.254-262

2017

Link zum Volltext

Verfügbarkeit prüfen

Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy

British journal of haematology, 2007-01, Vol.136 (1), p.63-72

2007

Link zum Volltext

Verfügbarkeit prüfen

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Blood, 2019-11, Vol.134 (Supplement_1), p.4315-4315

2019

Link zum Volltext

Verfügbarkeit prüfen

Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons

Current hematologic malignancy reports, 2009, Vol.4 (1), p.43-46

2009

Link zum Volltext

Verfügbarkeit prüfen

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

Blood, 2019-11, Vol.134 (Supplement_1), p.4318-4318

2019

Link zum Volltext

Verfügbarkeit prüfen

Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial

Blood, 2019-11, Vol.134 (Supplement_1), p.4305-4305

2019

Link zum Volltext

Verfügbarkeit prüfen

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Blood, 2019-11, Vol.134 (Supplement_1), p.4307-4307

2019

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia

The hematology journal : the official journal of the European Haematology Association, 2004, Vol.5 Suppl 1, p.S20

2004

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG)

Blood, 2019-11, Vol.134 (Supplement_1), p.4293-4293

2019

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Health-Related Quality of Life in Younger Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study Group

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial

Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia

Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG)

Suchergebnisse filtern